Jefferies Reiterates Buy Following Express Scripts' (ESRX) 3Q

October 26, 2016 9:26 AM EDT
Get Alerts ESRX Hot Sheet
Price: $70.56 -1.66%

Rating Summary:
    11 Buy, 17 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade ESRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies reiterated a Buy rating and $88.00 price target on Express Scripts (NASDAQ: ESRX) following the company's 3Q earnings report. EPS of $1.74 was 1c above consensus and was up 21% Y/Y.

Analyst Brian Tanquilut commented, "We're maintaining our Buy on ESRX given our view that its valuation at 10x FY17 P/E does not give credit to its ability to drive double-digit EPS growth (driven by cost cuts and buybacks) and strong FCF. While we acknowledge overhangs from ANTM and drug pricing pressure concerns, we also believe that ESRX's Q3 performance shows mgmt. commitment to offsetting these concerns and enhancing NT shareholder value through operational/cost adjustments and buybacks."

For an analyst ratings summary and ratings history on Express Scripts click here. For more ratings news on Express Scripts click here.

Shares of Express Scripts closed at $70.07 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Jefferies & Co, Earnings

Add Your Comment